News from ACC.25: oral semaglutide in high-risk DM2

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
ACC.25 – Darren McGuire shares the findings from the SOUL study, which demonstrated that treatment with oral semaglutide versus placebo led to a 14% relative reduction in MACE risk in high-risk T2D patients.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Darren McGuire is a cardiologist in the Division of Cardiology at the University of Texas Southwestern Medical Center in Dallas, TX, USA. He is a Distinguished Teaching Professor of Medicine with Tenure, is the Jere H. Mitchell, M.D. Distinguished Chair in Cardiovascular Science and is the Lead Physician of the Parkland Health Cardiology Clinics.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
Read our summary of the SOUL trial
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.

Recommended

Details

Presenters

Overview
ACC.25 – Darren McGuire shares the findings from the SOUL study, which demonstrated that treatment with oral semaglutide versus placebo led to a 14% relative reduction in MACE risk in high-risk T2D patients.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Darren McGuire is a cardiologist in the Division of Cardiology at the University of Texas Southwestern Medical Center in Dallas, TX, USA. He is a Distinguished Teaching Professor of Medicine with Tenure, is the Jere H. Mitchell, M.D. Distinguished Chair in Cardiovascular Science and is the Lead Physician of the Parkland Health Cardiology Clinics.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
Read our summary of the SOUL trial
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D